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Highlights 
 The use of antidepressants in pregnant women is a complex decision. 
 Recent studies investigated antidepressants in pregnancy and risk of ADHD in 
children. 
 Our meta-analysis confirmed the association between antidepressants and ADHD  
 However, our result did not support causality. 
 
 
Abstract: (164 words) 
This systematic review assesses the association between prenatal antidepressant exposure and risk of 
ADHD in children. Electronic databases were searched up to 25 July 2017. Observational studies 
examining this association were included in the review and meta-analysis was conducted where 
appropriate. Eight relevant studies were identified. The seven studies included in the meta-analysis 
comprised a total of 2,886,502 children. The pooled estimates comparing prenatal exposure to non-
exposure showed an adjusted rate ratio (aRR) of 1.39 (95%CI 1.21-1.61). Similarly, an increased risk 
was found comparing previous antidepressant users and non-users: aRR=1.56 (95%CI 1.25-1.95). The 
relationship between maternal psychiatric conditions and ADHD in children yielded an aRR of 1.90 
(95%CI 1.47-2.45). Three studies conducted sibling-matched analyses with aRR of 0.94 (95%CI 0.75-
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1.16). These data suggest that the observed association between prenatal use of antidepressants and risk 
of ADHD in offspring can be partially explained by confounding by indication because the results from 
sibling-matched analyses do not support an increased risk of ADHD in discordant exposed siblings. 
Keywords: Antidepressant; Pregnancy; Attention-Deficit/Hyperactivity Disorder. 
 
Main Text: 
1. Introduction 
1.1 Depression and antidepressants use in pregnancy 
Females are at higher risk of developing depression than males, particularly during 
pregnancy (Burke et al., 2005; Yonkers et al., 2009). Untreated depression during pregnancy 
has been associated with poor health outcomes for both mothers and children (Sontag-Padilla 
et al., 2013). The decision whether to use antidepressants during pregnancy is complex and 
requires that both clinician and patient consider the importance of reducing depressive 
symptoms, and the potential for adverse events affecting mother and child. Guidelines reflect 
this tension and generally recommend that antidepressants should be considered for pregnant 
women when it is judged that the benefits will outweigh the risk (Joint Formulary Committee, 
2014; National Institute for Health and Clinical Excellence, 2007).  
 
1.2 Attention-deficit/hyperactivity disorder (ADHD) in children 
ADHD is a neurodevelopmental disorder in children and adolescents characterised by 
pervasive hyperactivity, persistent inattention and impulsiveness, and which impairs the lives 
of children (American Psychiatric Association, 2013). ADHD is common among school-aged 
children with a worldwide prevalence of approximately 5-7% (Polanczyk et al., 2014; Thomas 
et al., 2015). Rates of diagnosis exceed this epidemiological prevalence in North America and, 
whilst ADHD is under-diagnosed in most other parts of the world, rates of identified cases in 
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other countries are increasing (Polanczyk et al., 2014). Due to the early onset, lifelong 
persistence, and high levels of associated comorbidities and impairment (Karam et al., 2015), 
the negative impact of ADHD on social outcomes, education and health of patients and their 
caregivers is significant (Fleck et al., 2015).  
 
1.3 Prenatal antidepressants exposure and the risk of ADHD in children 
Recent studies have suggested a potential link between maternal prenatal exposure to 
antidepressants, in particular, exposure to SSRIs, and the risk of ADHD in children (Boukhris 
et al., 2017; Castro et al., 2016; Clements et al., 2015; Figueroa, 2010; Laugesen et al., 2013; 
Malm et al., 2016; Man et al., 2017; Sujan et al., 2017).  Previous meta-analyses and large-
scale observational studies have also reported a possible association between prenatal exposure 
to antidepressants and autism spectrum disorder (ASD) in offspring (Man et al., 2015; Sujan et 
al., 2017). Given that both ADHD and ASD are major neurodevelopmental disorders in 
children and are sometimes concurrent (American Psychiatric Association, 2013), this adds to 
the concern about treating pregnant women with antidepressants and it is therefore important 
to determine whether prenatal exposure to antidepressant is an inherent risk factor for ADHD.  
Selective serotonin reuptake inhibitors (SSRIs) are the most frequently prescribed class 
of antidepressants, both in general, and during pregnancy. Recent meta-analyses have 
suggested that SSRI exposure during pregnancy is associated with preterm birth and low birth 
weight (Huang et al., 2014), congenital malformation (Myles et al., 2013), and persistent 
pulmonary hypertension (Grigoriadis et al., 2014). Antidepressants cross not only the blood-
brain barrier for intended pharmacological actions but also the placental barrier, and this could 
have unintended consequences for the developing foetus (Kendall-Tackett and Hale, 2010; 
Rampono et al., 2009). Animal studies have found that transient usage of fluoxetine during 
early development can result in abnormal emotional behaviour in adult mice, and this suggests 
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a potential modulation of serotonin transporters during development of the brain systems 
involved in emotional and stress related responses (Ansorge et al., 2004). Pharmacokinetic and 
pharmacodynamic data, albeit indirect and somewhat weak, suggest a plausible biological 
mechanism between in-utero exposure to antidepressants and ADHD in children (Ansorge et 
al., 2004; Kendall-Tackett and Hale, 2010; Pedersen, 2017).  Antidepressants primarily target 
the monoamine neurotransmitters such as serotonin and norepinephrine; neuronal proliferation, 
migration and axonal wiring are modulated by monoamines (Pedersen, 2017). Furthermore, 
the use of antidepressants during pregnancy is associated with an increased risk of several birth 
defects and adverse birth outcomes (Grigoriadis et al., 2014; Huang et al., 2014; Louik et al., 
2007; Myles et al., 2013), which may increase the risk of developing ADHD (National Institute 
for Health and Clinical Excellence, 2013). Placebo-controlled, randomised studies of the 
effects of maternal antidepressant use during pregnancy on the neurodevelopment of offspring 
are not feasible, and epidemiological studies therefore remain the most practical approach to 
investigating this association. Results from previous epidemiological studies are, however, 
inconsistent with contradictory findings (Boukhris et al., 2017; Castro et al., 2016; Clements 
et al., 2015; Figueroa, 2010; Laugesen et al., 2013; Malm et al., 2016; Man et al., 2017; Sujan 
et al., 2017). Evidence from most of the previous studies supports an association between 
prenatal antidepressant use and the risk of ADHD in children (Boukhris et al., 2017; Clements 
et al., 2015; Figueroa, 2010; Laugesen et al., 2013; Malm et al., 2016; Man et al., 2017; Sujan 
et al., 2017). However, some of these studies have emphasised that this association may be 
confounded by familial factors, and sibling-matched analyses do not support an increased risk 
(Laugesen et al., 2013; Man et al., 2017; Sujan et al., 2017). Further, those studies that used 
antidepressant exposure before pregnancy as a negative control also reported an increased risk 
for ADHD in offspring (Malm et al., 2016; Man et al., 2017; Sujan et al., 2017), suggesting 
that the observed increase in identified risk may have been confounded by maternal or familial 
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factors. Given these conflicting results, it has been difficult to reach a consensus as to whether 
there is a link between antidepressant use in pregnancy and ADHD in children.  
The possible link between prenatal antidepressant exposure and risk of 
neurodevelopmental disorders in childhood adds to the dilemma facing clinicians and patients 
in deciding how to manage severe affective disorders in women, both during pregnancy and at 
the time that they are trying to conceive. There can be significant unfavourable outcomes in 
terms of withholding or terminating antidepressant medication abruptly during pregnancy. In 
view of these issues, we undertook a systematic review and meta-analysis of published 
observational studies to evaluate the association between antidepressant exposure during 
pregnancy and ADHD in children. 
 
2. Methods 
2.1 Systematic literature search 
A systematic literature search was conducted using the search terms in Appendix 1. 
PubMed, EMBASE, PsycINFO and Cochrane Review database were searched up to 25 July 
2017. Observational studies, including cohort and case-control study designs, which 
investigated the association between antidepressant use in pregnancy and ADHD in children 
were included. In addition, sibling-matched studies that compared the exposure and outcome 
status among siblings born to the same mother were also included. Sibling-matched analysis 
can be applied in both cohort and case-control settings that compare the risk of outcome 
between exposed sibling(s) to non-exposed sibling(s) in cohort design; or the odds of exposure 
between case sibling(s) to control sibling(s) in case-control design. Case reports, animal studies 
and conference abstracts were excluded. English titles and abstracts were screened and full 
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texts of relevant articles were retrieved for further review to identify relevant studies. A hand-
search of selected articles was conducted to identify additional relevant studies. 
 
2.2 Quality assessment 
As recommended by the Cochrane Collaboration (Higgins and Green, 2011), the 
methodological quality of the included studies was assessed using the Newcastle-Ottawa Scale 
(NOS) (Wells et al., 2000). Separate NOS criteria were used for case-control and cohort 
studies. A maximum of nine stars could be allocated for the following categories: selection 
(definition of cases/exposed subjects, representativeness of the cases/exposed subjects, 
selection of control/non-exposed subjects), comparability (controls or adjustment for 
confounding factors) and outcome/exposure (assessment/ascertainment of outcome/exposure, 
adequate non-response rate or follow-up time). The total score was obtained by adding the 
number of stars in the sub-categories where a higher score indicates better quality. Authors KM 
and WL independently graded all included studies using the NOS criteria. 
 
2.3 Data extraction 
Data from included studies were extracted using a standardised data collection form. 
Extracted data included study duration and design, data source, covariates, exposure groups, 
and sample size. Authors KM and WL independently extracted data and completed the 
characteristics form that was subsequently cross-matched to ensure consistency and accuracy. 
Outcome parameters such as rate ratio (RR), odds ratio (OR), hazard ratio (HR) and the 
corresponding 95% confidence intervals (CI) were extracted and included in the meta-analysis 
if appropriate. The primary outcome of interest was the risk of developing ADHD in children 
following exposure to antidepressant, either at preconception (before pregnancy), or prenatal 
(during pregnancy). Definitions for “before pregnancy” and “during pregnancy” periods may 
AC
CE
PT
ED
 M
AN
US
CR
IPT
 8 
 
vary between studies. The corresponding definition from each study were summarised if 
available.  
 
2.4 Statistical analysis 
Four pooled estimates of ADHD risk in children were evaluated from the meta-analysis: 
1) Antidepressant use during pregnancy (prenatal user vs non-user); 2) Antidepressant use 
before pregnancy (previous user vs non-user); 3) Psychiatric conditions in mothers during 
pregnancy (yes vs no); 4) Sibling-matched antidepressant use in pregnancy. Both the crude and 
the fully adjusted rate ratios (RRs) were pooled in the meta-analysis. As the studies included 
in the analysis were conducted in different settings, we examined the extent of heterogeneity 
among studies with the Cochran Q test (Higgins and Green, 2011), where a cut-off p-value of 
0.1 was considered significant for heterogeneity. Higgins' I2-statistic (Higgins and Green, 
2011) was reported for each figure. The pooled estimates were calculated using DerSimonian 
and Laird’s random-effects model (DerSimonian and Laird, 1986) to account for heterogeneity 
among studies. Analysis was performed on both the crude and adjusted estimates from the 
studies. The pooled estimates with 95% CI were calculated. Subgroup analysis was conducted 
by stratifying studies with different study designs. If more than one study shared the same data 
source, the meta-analysis only included one study from the same data source. Sensitivity 
analyses were performed by substituting these studies one by one. Post-hoc sensitivity analyses 
were conducted by restricting the analyses of 1) Prenatal exposure, 2) Pre-conception exposure, 
and 3) Maternal psychiatric conditions to studies explicitly stating that the three groups 
contained no overlapping individuals as we do not have information on the proportion of 
overlapping/non-overlapping groups in some of the studies. All probability values (two tailed) 
with a p-value of 0.05 were considered statistically significant. All analyses were conducted 
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using Review Manager 5.2 (Copenhagen: The Nordic Cochrane Centre, The Cochrane 
Collaboration, 2012). 
 
3. Results 
3.1 Summary of literature 
PubMed, EMBASE, PsycINFO and the Cochrane Review databases were searched; 
yielding 134, 309, 99 and 0 records respectively, with a total of 542 articles, from January 1946 
to 25 July 2017. After the removal of duplicates, 431 records remained. Titles and abstracts 
were screened and full texts of relevant articles were retrieved for further review with 423 
studies meeting the exclusion criteria. The systematic literature search returned eight 
observational studies (Figure 1) (Boukhris et al., 2017; Castro et al., 2016; Clements et al., 
2015; Figueroa, 2010; Laugesen et al., 2013; Malm et al., 2016; Man et al., 2017; Sujan et al., 
2017). All studies utilised electronic healthcare databases or national registries as data sources. 
Disease codes, such as International Classification of Diseases, Eighth, Ninth or Tenth (ICD-
8, ICD-9 and ICD-10) were used to identify outcomes. Three studies were from the US (Castro 
et al., 2016; Clements et al., 2015; Figueroa, 2010), three from Nordic countries: Laugesen et 
al. from Denmark, Malm et al. from Finland and Sujan et al. from Sweden (Laugesen et al., 
2013; Malm et al., 2016; Sujan et al., 2017), one from Canada (Boukhris et al., 2017), and one 
from Hong Kong (Man et al., 2017). Study commencement dates ranged from 1996 to 2001. 
A summary of the included studies is shown in Table 1. Included studies were of adequate 
quality with respect to study design, obtaining more than seven out of nine stars from the NOS 
quality assessment (eTable 1). Two included studies, Castro et al. (Castro et al., 2016) and 
Clements et al. (Clements et al., 2015) used the same data source. Clements et al. was used for 
the primary analysis as this included more subjects, and a sensitivity analysis was conducted 
by substituting Castro et al. for Clements et al. in the meta-analysis. Six other studies (five 
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cohort studies, one case-control study) (Boukhris et al., 2017; Figueroa, 2010; Laugesen et al., 
2013; Malm et al., 2016; Man et al., 2017; Sujan et al., 2017) were also eligible for the meta-
analysis. 
 
3.2 Antidepressant exposure during pregnancy (Prenatal exposure)  
The seven studies entered into the meta-analysis included a total of 2,886,502 children 
(Boukhris et al., 2017; Clements et al., 2015; Figueroa, 2010; Laugesen et al., 2013; Malm et 
al., 2016; Man et al., 2017; Sujan et al., 2017). Pregnancy period was defined by Boukhris et 
al., Clements et al., Castro et al. and Man et al. as any time between the last menstrual period 
and delivery, whereas Sujan et al. defined this as time from 90 days before estimated 
conception to delivery. Laugesen et al. and Malm et al defined pregnancy period as “30 days 
before pregnancy until the end of pregnancy” and Figueroa defined this as time between 279 
days before delivery to date of delivery. The pooled estimates comparing prenatal users to non-
users showed crude and adjusted RRs of 2.14 (95%CI 1.96-2.33) and 1.39 (95%CI 1.21-1.61), 
respectively (Figure 2a and eFigure 1a). Low heterogeneity was found between studies in the 
crude estimate (Q-statistics=8.44, p=0.21; I2=29%) but high heterogeneity in the adjusted 
estimate (Q-statistics=30.1, p<0.01; I2=80%).  
The corresponding risk ratios in the first and second trimester were similar. The pooled 
adjusted RR in the first and second trimester were 1.26 (95%CI 1.01-1.57) and 1.42 (95%CI 
1.18-1.73), respectively. However, the pooled adjusted RR in the third trimester was 1.05 
(95%CI 0.74-1.48) (eFigure 2).  
 
3.3 Antidepressant exposure before pregnancy (Pre-conception exposure)  
Five studies provided information on antidepressant exposure before pregnancy and 
risk of ADHD in children (Clements et al., 2015; Figueroa, 2010; Malm et al., 2016; Man et 
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al., 2017; Sujan et al., 2017). Slightly different definitions for “before pregnancy” were used 
for these studies. Clements et al., Castro et al. and Man et al. defined previous exposure as “any 
time before last menstrual period” whereas Sujan et al. defined before pregnancy as “between 
270 and 90 days before estimated conception”. Malm et al defined this as “one year before 
pregnancy until three months before pregnancy” and Figueroa defined this as “the year before 
pregnancy” (Table 1). Similar to the results for prenatal exposure, an increased risk was found 
when comparing previous antidepressant users and non-users: crude RR=2.20 (95%CI 1.75-
2.77), adjusted RR=1.56 (95%CI 1.25-1.95). Heterogeneity was significant for the crude 
estimate (Q-statistics=12.22, p=0.02; I2=67%) and the adjusted estimate (Q-statistics=9.47, 
p=0.05; I2=58%) (Figure 2b and eFigure 1b).  
 
3.4 Maternal psychiatric conditions  
The relationship between maternal psychiatric conditions and ADHD in children was 
evaluated in five studies (Boukhris et al., 2017; Clements et al., 2015; Figueroa, 2010; Malm 
et al., 2016; Man et al., 2017). Maternal psychiatric conditions during pregnancy yielded a 
pooled crude RR of 2.40 (95%CI 1.81-3.17) (Q-statistics=60.60, p<0.01; I2=93%) and adjusted 
RR of 1.90 (95%CI 1.47-2.48) (Q-statistics=47.99, p<0.01; I2=92%) (Figure 2c and eFigure 
1c).  
 
3.5 Sibling-matched antidepressant exposure during pregnancy 
 Three studies conducted sibling-matched analyses (Laugesen et al., 2013; Man et al., 
2017; Sujan et al., 2017). The pooled RR of exposed sibling was 0.94 (95%CI 0.75-1.16) (Q-
statistics=1.75, p=0.42; I2=0%) (Figure 3). 
 
3.6 Sensitivity Analyses 
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No material difference in the pooled estimates of any analyses were found when 
Clements et al. was replaced with Castro et al. (eFigure 3-5). The pooled estimates comparing 
prenatal users to non-users showed adjusted RRs of 1.34 (95%CI 1.17-1.54) (eFigure 3b). The 
corresponding pooled estimate for pre-conception exposure and maternal psychiatric 
conditions was 1.77 (95%CI 1.52-2.06) and 1.66 (95%CI 1.30-2.11) respectively (eFigure 4b 
and eFigure 5b). 
Post-hoc sensitivity analyses were conducted by restricting the analyses of 1) Prenatal 
exposure, 2) Pre-conception exposure, and 3) Maternal psychiatric conditions to only those 
explicitly stating that the three groups contained no overlapping individuals (Malm et al., 2016; 
Man et al., 2017; Sujan et al., 2017). The pooled estimates comparing prenatal users to non-
users showed adjusted RRs of 1.57 (95%CI 1.46-1.69). The corresponding pooled estimate for 
pre-conception exposure and maternal psychiatric conditions was 1.82 (95%CI 1.54-2.15) and 
1.80 (95%CI 1.56-2.08), respectively (eTable 2). The results are similar to our original 
analyses. 
 
4. Discussion 
4.1 Summary of main results 
 To our knowledge, this is the first systematic review and meta-analysis of 
antidepressant use in pregnancy and the risk of ADHD in children. Previous population-based 
studies, with the exception of Castro et al., reported similar results with an increased risk of 
ADHD associated with prenatal exposure to antidepressants which ranged from 1.16 to 1.81 
(Boukhris et al., 2017; Clements et al., 2015; Figueroa, 2010; Laugesen et al., 2013; Malm et 
al., 2016; Man et al., 2017; Sujan et al., 2017). Likewise, similar results were observed for pre-
conception exposure to antidepressants with adjusted risk ratios ranging from 1.18 to 2.09 
(Clements et al., 2015; Malm et al., 2016; Man et al., 2017; Sujan et al., 2017). There has been 
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little biological explanation about why antidepressant exposure before pregnancy should result 
in ADHD in the offspring. Based on the effect of psychiatric disorder on ADHD and pre-
conception exposure, it is likely that this increased risk may be partially explained by 
confounding due to pre-existing conditions.  
 
4.2 Possibility of confounding by maternal psychiatric conditions 
Indeed, previous studies have observed that maternal psychiatric conditions are risk 
factors for having ADHD offspring (Castro et al., 2016; Clements et al., 2015; Figueroa, 2010; 
Malm et al., 2016; Man et al., 2017). ADHD is highly heritable (Ronald et al., 2008; Smalley, 
1997) and parents of children with ADHD are therefore more likely to suffer from ADHD. In 
recent years, it has become apparent that ADHD often persists into adulthood, and, when it 
does, it is associated with high levels of psychiatric comorbidity, including increased rates of 
depression and anxiety. However, it is also the case that most adults with ADHD are currently 
never properly diagnosed or treated (Asherson et al., 2012). Boukhris and colleagues (Boukhris 
et al., 2017) included maternal history of ADHD as a covariate in their analysis; however, only 
186 out of 144,406 (0.13%) mothers had a record of ADHD diagnosis. This may explain why 
we found a possible link between psychiatric disorders in mothers and ADHD in children.  
Confounding by genetic factors cannot be ruled out through population-wide 
comparisons. To address this, three studies investigated a within-family association (Laugesen 
et al., 2013; Man et al., 2017; Sujan et al., 2017). These same three studies further investigated 
this possibility through sibling-matched analyses (Laugesen et al., 2013; Man et al., 2017; 
Sujan et al., 2017), comparing exposure- and outcome-discordant offspring among siblings 
born to the same mother. All three analyses found no increased risk of ADHD in siblings with 
prenatal antidepressant exposure (pooled hazard ratio=0.94; 95%CI 0.75-1.16) (Laugesen et 
al., 2013; Man et al., 2017; Sujan et al., 2017). Sibling-matched design is useful in accounting 
AC
CE
PT
ED
 M
AN
US
CR
IPT
 14 
 
for confounding of the exposure with all familial and environmental factors that are shared in 
common by the siblings, in particular genetic confounding (D'Onofrio et al., 2013). Clearly, 
there are differences between the results of population-based cohort studies and carefully 
controlled sibling cohort studies in our meta-analysis. The sibling-matched analyses are, in 
general, better regarded for controlling confounding factors at family level; such differences in 
methodology, as shown in our results, strongly support the argument that the association 
between antidepressant use in pregnancy and ADHD in offspring is likely to be confounded by 
psychiatric disorders in the family or other environmental factors (unmeasured confounders), 
which cannot be controlled for in population-based cohort studies.  
Nonetheless, we must acknowledge that sibling-matched studies require several 
assumptions. Sibling-comparison designs cannot rule out confounding factors that vary within 
siblings and that are highly correlated with both the exposure and the outcome such as maternal 
age (D'Onofrio et al., 2013; Sjolander and Zetterqvist, 2017). In addition, sibling comparisons 
are based on strict assumptions about carry-over effects (i.e. the possibility that exposure of a 
sibling influences the outcome of another) (Lahey and D'Onofrio, 2010).  
 
4.4 Other study designs that address potential confounding effects 
With respect to the limitations of the sibling-matched design, some of the included 
studies provided alternative analyses that addressed for confounding effect in this association. 
Two studies compared mothers who continued antidepressants during pregnancy with those 
who discontinued antidepressants prior to becoming pregnant (Man et al., 2017; Sujan et al., 
2017). Man et al. (Man et al., 2017) conducted direct comparison between the continuing users 
and users who discontinued with HR=0.75 (95%CI 0.51-1.10). On the other hand, Sujan et al. 
(Sujan et al., 2017) investigated whether the risk estimate for continuing users and the 
discontinued users was statistically different from each other. They found no significant 
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difference between the two groups (p-value=0.49) which suggests no increased risk of ADHD. 
In addition, Man et al. (Man et al., 2017) used maternal antipsychotic treatment as an active 
comparator to antidepressants. As confounding by indication is likely to be an important issue 
in this association, comparing individuals with treatment to those without treatment may induce 
bias (Schneeweiss et al., 2007). By comparing gestational use of antidepressants to gestational 
use of antipsychotics, Man et al. found no difference in the risk of ADHD between these groups 
(hazard ratio=1.27, 95%CI 0.73-2.18) which support the argument of confounding by 
indication. Sujan et al. (Sujan et al., 2017) applied a negative control analysis by considering 
antidepressant exposure in fathers during the childbearing period of their partner. Interestingly, 
an increased risk of ADHD in offspring was identified when fathers were exposed to 
antidepressants during the pregnancy of their partners (hazard ratio=1.73, 95%CI 1.38-2.17) 
(Sujan et al., 2017). As the medication in the father has no biological contact with the foetus, 
this finding supports the argument that the observed association is confounded by non-
pharmacological factors. The findings suggest that the observed association is likely to be 
affected by unmeasured confounding factors within the family, such as family health conditions 
and genetic factor.  
 
4.5 Availability of data sources and methodological challenges in previous studies 
Few studies have investigated the association between antidepressant use in pregnancy 
and the risk of ADHD in children. This may reflect the complexities involved in designing and 
conducting this type of study. Interventional studies are not deemed to be ethical in the clinical 
setting, and therefore observational studies appear to be the only practical way to investigate 
these associations. However, obtaining a large sample size in non-database studies remains 
challenging, and achieving long term follow-up in the cohort setting, together with recall bias 
in the case-control setting are major methodological limitations to carrying out such studies 
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and drawing unbiased conclusions about the findings. Now that data linkage between mother 
and child data is becoming more common, further large scale database studies, preferably with 
sibling-matched analyses, are warranted to address these potential associations. 
Castro et al. and Clements et al. obtained their study sample from the same data source 
using similar methodologies but reported different results (Castro et al., 2016; Clements et al., 
2015). When compared with Clements et al., Castro et al. used a different matching criteria 
resulting in a smaller sample size (5,498 in Castro et al., 7,874 in Clements et al.) and a less 
precise estimate (adjusted odds ratio=0.97, 95%CI 0.56-1.69). 
 
4.6 Clinical implications 
 It is important to emphasise that antidepressants should not be stopped abruptly or 
withheld during pregnancy due to concerns about the risk of ADHD in the offspring. This could 
lead to maternal depression deteriorating. Untreated pregnant women with depression are more 
at risk of developing postpartum depression and suicidality (Andersson et al., 2004). The 
negative consequences of untreated maternal depression might also affect the child’s 
development and higher impulsivity, maladaptive social interactions, and cognitive, 
behavioural, and emotional difficulties have been shown to occur (Bennett et al., 2004; Bonari 
et al., 2004). Our study has shown that for mothers who had either taken antidepressants during 
pregnancy or only before pregnancy, the risk of ADHD among their children was similar. 
Therefore, in view of the current evidence, pregnant women should not stop treatment due to 
concerns of ADHD in their children.  
 
4.7 Strengths and limitations 
We undertook a rigorous systematic review and meta-analysis which included all 
relevant literature to date. Reviewer selection bias was minimised by using a predefined search 
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strategy for selection and data extraction was conducted by two independent authors. All 
included studies were conducted with large databases which provided a relatively large sample 
size for the studies.  
 Differences in study designs, exclusion criteria, control groups selection, duration of 
follow-up, exposure definitions, outcome definitions, included covariates and analysis model 
can affect the accuracy of pooled estimates for both crude and adjusted ORs. In addition, how 
pregnancy information is stored and retrieved in each study database, may explain the different 
study designs and definitions. We observed low heterogeneity in the crude pooled estimate but 
high heterogeneity in the adjusted pooled estimate. This may represent the difference in the 
analysis for each study, in particular, which covariates were included, and what analysis model 
was used, therefore, results with high heterogeneity should be interpreted with caution. 
However, all studies were essentially measuring the same outcomes and there is no indication 
of large clinical heterogeneity to invalidate our meta-analysis. More importantly, the forest 
plots of all analyses are consistent and the conclusions are consistent with biological 
plausibility; thus, we believe it is appropriate to numerically summarise all results in this 
systematic review. 
 Our meta-analysis included three main comparisons: mothers exposed during 
pregnancy, mothers exposed before pregnancy, and mothers with psychiatric conditions. Just 
three of the included studies (Malm et al., 2016; Man et al., 2017; Sujan et al., 2017), stated 
clearly that there was no overlapping individuals in these groups, whilst this was not clear for 
the other included studies. However, all studies provided adjusted estimates for the three 
groups. For example, the adjusted estimate for “prenatal exposure” was adjusted for previous 
exposure and/or maternal psychiatric conditions. The different methodological approaches of 
the included studies are reflected in the heterogeneity index. Nevertheless, the results were 
similar to the original analysis in the post-hoc sensitivity analyses by restricting the analyses 
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to Malm et al., Man et al. and Sujan et al. Thus, we believe this would not alter our study 
conclusion. 
 
 Only two studies (Figueroa, 2010; Man et al., 2017) restricted their sample to children 
who were at least five years old at the time of assessment whereas the others did not apply any 
age constraints up to five years old (Boukhris et al., 2017; Castro et al., 2016; Clements et al., 
2015; Laugesen et al., 2013; Malm et al., 2016; Sujan et al., 2017). As ADHD is much less 
likely to be diagnosed clinically before the age of five years, these studies may have identified 
unrepresentative samples with significant proportions of children under age five, leading to 
biased estimates of the actual risk.  
  
 In addition, all studies relied on a clinical diagnosis of ADHD being made (Castro et 
al., 2016; Clements et al., 2015; Figueroa, 2010; Laugesen et al., 2013; Malm et al., 2016; 
Sujan et al., 2017). This may impact differently on individual study results with possibly 
different diagnostic criteria or different local practices that consequently affect the pooled 
estimates. We could only estimate the prevalence of ADHD in the cohort studies (Boukhris et 
al., 2017; Laugesen et al., 2013; Malm et al., 2016; Man et al., 2017; Sujan et al., 2017). The 
prevalence of ADHD in the Scandinavian studies ranged from 0.6% to 2.1%, this was 3.2% in 
the Canada study and 3% in the Hong Kong study. All are lower than the rate in 
epidemiological studies which suggest a global prevalence of around 5% (Polanczyk et al., 
2014). A low prevalence of ADHD in the Scandinavian studies may be due to the inclusion of 
children aged under 5 years and may also be due to the nature of register-based studies where 
only clinically detected cases are included. This is a limitation that applies to all of the included 
studies. Under-diagnosis of less severe ADHD cases in control groups could account for 
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outcome misclassification that would bias the estimates towards null; hence, we may have 
underestimated the actual risk but this is unlikely to affect the conclusion.   
As the number of studies included in the meta-analysis was limited, a funnel plot was 
not performed and it was not possible to assess for publication bias. In addition, the studies 
identified for meta-analysis are all relatively recent (2010-2017) and present similar results. 
We cannot, therefore, exclude the possibility of publication bias. As a result, the pooled 
estimates may be overestimated.  
 
5. Conclusions 
 In conclusion, in this systematic review and the meta-analysis of existing studies, 
although an increased risk of ADHD in the offspring of mothers treated with antidepressant 
during pregnancy was observed, maternal exposure to antidepressants before pregnancy, as 
well as mothers being diagnosed with a psychiatric disorder, showed similar results. Similarly, 
sibling-matched studies do not support an increased risk of ADHD in the offspring of mothers 
treated with antidepressants during pregnancy. Therefore, it can be concluded that the 
association of ADHD in offspring with maternal prenatal antidepressant exposure is likely to 
be confounded by other factors.  
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Figure and Tables 
Figure 1: Flowchart for studies inclusion  
Figure 2: Forest plot of the meta-analysis 
Figure 3: Forest plot of the sibling-matched analysis 
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Table 1:  Summary of included studies  
Table 2:  Summary of included studies’ results  
 
Table 1:  Summary of included studies 
Study Data Source 
Study 
period 
Country Case definition Exclusion criteria 
Selection of comparison 
group 
Exposure duration 
definition 
Boukhris 
2017 
Data from the Quebec 
Pregnancy/Children Cohort 
(QPC) with linkage to three 
administrative databases: the 
Regie de l’assurance maladie 
du Quebec (RAMQ), 
Quebec’s Public Prescription 
Drug Insurance database, and 
the Quebec hospitalisation 
archive (MedEcho) database. 
1998-
2009 
Canada All children with a 
diagnosis of ADHD or at 
least one prescription 
ﬁlled for ADHD 
medications between 
birth and the end of 
follow-up.  
ADHD diagnosis was 
deﬁned as a medical 
service claim or 
hospitalisation with a 
diagnosis of ADHD 
according to ICD-9 
codes: 314; ICD-10:F90 
All births that were 
not full-term birth 
(<37 weeks of 
gestation); non-
singleton birth; 
children with autism 
spectrum disorder; or 
mothers who were not 
covered for at least 12 
months in the 
database were 
excluded. 
Women without 
antidepressants 
prescriptions 
Exposures were 
identified from 
RAMQ prescription 
database. At least 
one prescription 
ﬁlled at any time 
during pregnancy or 
a prescription ﬁlled 
before pregnancy 
that overlapped the 
first day of gestation 
Castro 
2016 
Three independent electronic 
health records: the Partners 
HealthCare system, which 
spans Massachusetts General 
Hospital (MGH), Brigham 
and Women’s Hospital and 
Newton-Wellesley Hospital, 
1997-
2010 
United 
States 
Children age 2 -19 years 
with at least one ICD-9 
code of 314.x and no 
ICD-9 code of 299 
between 1997 and 2010, 
delivered at MGH, 
Brigham and Women’s 
If mother -child 
matches could not be 
conﬁrmed, those pairs 
were omitted from 
analysis. Restricted 
the analysis to one 
child per mother, 
Children were then 
matched 1:3 with healthy 
control children delivered 
at MGH, Brigham and 
Women’s Hospital, 
Newton-Wellesley 
Hospital or BIDMC with 
Exposures were 
identiﬁed            
using e-prescribing 
data in the EHR, 
both inpatient and 
outpatient, which 
record number of 
pills, frequency and 
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as well as afﬁliated outpatient 
clinics; the Beth Israel 
Deaconess Medical Center 
(BIDMC); and the Boston 
Children’s Hospital. 
Additional maternal and 
paternal data, as well as 
conﬁrmation of matching 
accuracy between mothers 
and offspring were obtained 
from the Massachusetts 
Registry of Vital Records and 
Statistics. 
Hospital, Newton-
Wellesley Hospital or 
BIDMC.  
choosing the child 
with ADHD when a 
mother had both a 
case and control 
offspring. When two 
case or two control 
children were 
identiﬁed from one 
mother we randomly 
selected one child for 
inclusion in the study. 
the same year of birth, 
birth hospital, sex, 
insurance type as a proxy 
for socioeconomic status, 
race/ethnicity and 
preterm versus full-term 
status. Children with any 
history of ASD, ADHD 
or intellectual disability 
(ICD-9 of 299, 314 or 
317 -319) were excluded 
from the control 
population. If fewer than 
three matches could be 
identiﬁed for a case, year 
of birth was relaxed so 
that controls were born 
within 3 years of a given 
case. 
reﬁll number, 
allowing calculation 
of exposure period.  
Previous exposure 
defined as exposure 
at any time before 
last menstrual 
period. 
Clements 
2015  
Three independent electronic 
health records: the Partners 
HealthCare system, which 
spans Massachusetts General 
Hospital (MGH), Brigham 
and Women’s Hospital and 
Newton-Wellesley Hospital, 
as well as afﬁliated outpatient 
clinics; the Beth Israel 
Deaconess Medical Center 
(BIDMC); and the Boston 
Children’s Hospital. 
Additional maternal and 
paternal data, as well as 
1997-
2010 
United 
States 
Children age 2 -19 years 
with at least one ICD-9 
code of 314.x and no 
ICD-9 code of 299 
between 1997 and 2010, 
delivered at MGH, 
Brigham and Women’s 
Hospital, Newton-
Wellesley Hospital or 
BIDMC. 
If mother -child 
matches could not be 
conﬁrmed, those pairs 
were omitted from 
analysis. Restricted 
the analysis to one 
child per mother, 
choosing the child 
with ADHD when a 
mother had both a 
case and control 
offspring. When two 
case or two control 
children were 
Children were then 
matched 1:3 with healthy 
control children delivered 
at MGH, Brigham and 
Women’s Hospital, 
Newton-Wellesley 
Hospital or BIDMC with 
the same year of birth, 
birth hospital, sex, 
insurance type as a proxy 
for socioeconomic status, 
race/ethnicity and 
preterm versus full-term 
status. Children with any 
Exposures were 
identiﬁed using e-
prescribing data in 
the EHR, both 
inpatient and 
outpatient, which 
record number of 
pills, frequency and 
reﬁll number, 
allowing calculation 
of exposure period.  
Previous exposure 
defined as exposure 
at any time before 
last menstrual 
period. 
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conﬁrmation of matching 
accuracy between mothers 
and offspring were obtained 
from the Massachusetts 
Registry of Vital Records and 
Statistics. 
identiﬁed from one 
mother we randomly 
selected one child for 
inclusion in the study. 
history of ASD, ADHD 
or intellectual disability 
(ICD-9 of 299, 314 or 
317 -319) were excluded 
from the control 
population. If fewer than 
three matches could be 
identiﬁed for a case, year 
of birth was relaxed so 
that controls were born 
within 3 years of a given 
case. 
Figueroa 
2010 
MarketScan data, collected by 
Thompson Reuters 
(previously Medstat), are 
obtained from large self-
insured employers from all 
states, except Alaska and 
Hawaii. 
1996-
2006 
United 
States 
Live born who were 
born during 1997–2002 
to mothers aged 15 to 50 
years. Only the first 
delivery was included. 
Delivery hospitalizations 
were identified by the 
International 
Classification of 
Diseases, Ninth 
Revision, Clinical 
Modification (ICD-9-
CM) codes V27 and 650, 
by diagnosis-related 
group codes 370 to 375 
Excluding any ICD-9-
CM codes 
incompatible with a 
live delivery (e.g., 
abortion, ectopic 
pregnancy; i.e., 630–
639). 
All children whose 
length of observation 
was less than 4years 
after the delivery date 
were excluded. 
Children without claims 
with a primary or 
secondary diagnosis of 
ADHD and prescription 
claims for stimulants 
National drug coding 
numbers were used 
to identify specific 
medications.  
Antidepressants 
were grouped by 
their mechanism of 
action into 3 
groups: selective 
serotonin reuptake 
inhibitors, 
bupropion, 
and other 
antidepressants 
(tricyclics, 
tetracyclics, 
mirtazapine, and 
venlafaxine).  
Exposure before 
pregnancy defined as 
any exposure in the 
year before 
pregnancy. 
AC
CE
PT
ED
 M
AN
US
CR
IPT
 30 
 
Laugesen 
2013 
Danish Medical Birth 
Registry; Danish National 
Prescription Registry; Danish 
Psychiatric Central Register; 
Danish Civil Registration 
System; Danish National 
Hospital Register 
1996-
2009 
Denmark All singletons born alive 
from 1996 until the end 
of 2009. ADHD was 
detected either as a 
diagnosis of ADHD or 
redemption of a 
prescription for ADHD 
medication 
Patients with missing 
data were excluded 
from the analyses 
Women without 
antidepressants 
prescriptions from 30 
days before conception to 
the day of birth 
In utero exposure to 
antidepressants was 
deﬁned as 
maternal redemption 
of a prescription for 
an antidepressant 
30 days prior to or 
during pregnancy, as 
identiﬁed 
through the Danish 
National Prescription 
Registry  
Malm 
2016 
Finland Medical Birth 
Register, the Register of 
Congenital Malformations, 
the Hospital Discharge 
Register including inpatient 
and outpatient data, the Drug 
Reimbursement Register, and 
the Population Register 
1996-
2010 
Finland Singleton live births in 
Finland between January 
1, 1996, and December 
31, 2010 
Excluded individuals 
with a depression 
diagnosis only during 
the ﬁrst 2 years of life 
if the diagnosis was 
not recorded at later 
stages.  
Mothers without SSRI 
prescriptions 
Mothers in the SSRI 
exposed group had 1 
or more purchases of 
SSRIs during 
the period from 30 
days before 
pregnancy until the 
end of pregnancy. 
Exposure before 
pregnancy defined as 
exposure at one year 
before pregnancy 
until three months 
before pregnancy 
Man 
2017 
Data from Hong Kong 
Clinical Data Analysis and 
Reporting System that 
includes electronic health 
record in all public hospitals 
and their associated 
ambulatory clinics  
2001-
2015 
Hong 
Kong 
Liveborn children with 
an ADHD diagnosis, 
registered as ICD-9-CM 
diagnosis code 314, or a 
prescription for an 
ADHD drug, namely 
methylphenidate or 
atomoxetine 
Children with: 
missing mother-child 
link; perinatal death; 
abortion case; missing 
gestation week; 
missing gender; 
missing Apgar score 
at 1 minute or 5 
minute; date of 
conception outside 
Children with mothers 
who did not have 
antidepressant exposure 
during pregnancy 
Antidepressant use 
in mothers was 
extracted from the 
prescribing and 
dispensing records in 
CDARS. All drugs 
in 
the British National 
Formulary chapter 
4.3 were included. 
Previous exposure 
defined as exposure 
at any time before 
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study period, were 
removed 
last menstrual 
period. 
Sujan 
2017 
Swedish registries: the Multi-
Generation Register; the 
Prescribed Drug Register; 
Medical Birth Register; 
National Patient Register; 
National Crime Register; 
Swedish Register of 
Education 
1996-
2012 
Sweden Children with first 
diagnosis of ADHD, 
which were identified 
using inpatient and 
outpatient diagnoses 
made by specialists 
according to ICD-9 and 
ICD-10.  
Cases of multiple 
births, those with a 
missing father 
identifier, missing 
invalid response on 
covariates, and 
missing the small for 
gestational age 
variable were 
excluded. 
Children with mothers 
who did not have 
antidepressant exposure 
in the first trimester.  
Main exposure 
evaluated were first 
trimester exposure to 
any antidepressants. 
With Anatomical 
Therapeutic 
Chemical 
Classification (ATC) 
codes beginning with 
N06A. 
Exposure before 
pregnancy defined as 
exposure between 
270 and 90 days 
before estimated 
conception. 
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Table 2:  Summary of included studies’ results 
Study 
Number of 
participants 
Number of events 
Crude 
ORa/RRb/HRc 
Factors considered during adjusted 
analysis 
Adjusted 
OR/RR/HR 
Boukhris 
2017 
144,406 Antidepressants group: 267 with ADHD; 4411 without 
ADHD 
Unexposed group: 4297 with ADHD; 135431 without 
ADHD 
1.86e 
(95% CI 1.65-2.09) 
Gender, birth year, maternal age, maternal 
education level, recipient of social 
assistance, area of residence, maternal 
psychiatric disorders in the year prior to or 
during pregnancy (depression/anxiety, 
other psychiatric disorders), maternal co-
morbities (gestational diabetes, gestational 
hypertension), maternal history of ADHD 
1.20 
(95% CI 1.00-1.40) 
Castro 2016 5,498 ADHD group: 29 with antidepressant; 1672 without 
antidepressant 
Control group: 57 with exposure; 3740 without 
exposure 
0.91 
(95% CId 0.56-1.42) 
Gender, race, birth year, insurance type, 
median income tertile, past history of 
maternal depression 
0.97 
(95% CI 0.53-1.69) 
Clements 
2015 
7,874 ADHD group: 63 with antidepressant; 2180 without 
antidepressant 
Control group: 68 with antidepressant; 5563 without 
antidepressant 
2.30 
(95% CI 1.62-3.24) 
Gender, race, birth year, insurance type, 
median income tertile, past history of 
maternal depression 
1.81 
(95% CI 1.22-2.70) 
Figueroa 
2010 
38,074 ADHD group: 23 with SSRI, 5 with Bupropion, 1 with 
other antidepressant; 402 without antidepressant 
Control group: 893 with SSRI, 109 with Bupropion, 
118 with other antidepressant; 36925 without 
antidepressant 
2.35e 
(95% CI 1.61-3.45) 
Maternal age group, gender of the 
child, urban or rural metropolitan 
statistical area, year of birth, age at last 
claim and at end of eligibility, maternal 
and paternal mental health diagnoses, the 
presence or absence of maternal mental 
health-related visits by period of time, the 
use of other psychotropics during 
pregnancy, and perinatal complications 
1.16e 
(95% CI 0.72-1.90) 
 
 
Laugesen 
2013 
877,778 Antidepressants group: 432e with ADHD, 14576e 
without ADHD 
2.00 Gender of the child, calendar time at birth, 
birth order, maternal age at birth, maternal 
smoking status, maternal psychiatric 
diagnoses, paternal psychiatric diagnoses, 
1.20 
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Unexposed group: 12409e with ADHD, 850361e 
without ADHD 
(95% CI 1.70-2.30) maternal diseases during pregnancy 
(infections, epilepsy) and maternal 
anxiolytics/hypnotics/sedatives use during 
pregnancy 
(95% CI 1.10-1.40) 
Malm 2016 47,123 SSRIs group: 160 with ADHD; 15569 without ADHD 
Unexposed group: 124 with ADHD; 31270 without 
ADHD 
2.62 
(95% CI 2.06-3.34) 
Sex; socioeconomic status; smoking 
during pregnancy; neonatal care unit; 
maternal history of other psychiatric 
diagnosis; maternal history of substance 
abuse; paternal history of psychiatric 
diagnosis; parental death 
1.66 
(95% CI 1.27-2.16) 
Man 2017 190,618 Antidepressant group: 74 with ADHD; 1,178 without 
ADHD 
Unexposed group: 5,585 with ADHD; 183,781 without 
ADHD 
 
2.26 
(95%CI 1.80-2.84) 
Maternal age at delivery, infant’s sex, birth 
year, birth hospital, parity, maternal 
underlying medical conditions before 
delivery (pre-existing diabetes, epilepsy, 
gestational diabetes, psychiatric 
conditions, hypertension), use of other 
psychotropic drugs (antipsychotics, 
British National Formulary chapter 4.2.1, 
4.2.2), and socioeconomic status. 
1.39 
(95%CI 1.07-1.82) 
Sujan 2017 1,580,629 Antidepressant group:613 with ADHD; 21931 without 
ADHD 
Unexposed group: 32311 with ADHD; 1525774 
without ADHD 
2.21 
(95%CI 2.04-2.39) 
Parity; year of birth; country of birth; age 
at childbearing; highest level of completed 
education; history of any criminal 
conviction; history of severe psychiatric 
illnesses (inpatient diagnosis of ICD-8, 
ICD-9, or ICD-10 schizophrenia, bipolar 
disorder, or other non-drug-induced 
psychoses); and history of any suicide 
attempts. 
1.58 
(95% CI 1.46-1.71) 
aOR=Odds Ratio 
bRR=Rate Ratio,  
cHR=Hazard Ratio  
d95% CI=95% confidence interval 
eFigures were not directly available, calculated by the figures given in the study
 
AC
CE
PT
ED
 M
AN
US
CR
IPT
